This retrospective longitudinal study explored early changes in anatomical, perfusion, and diffusion MRI in patients with IDH-mutant gliomas during treatment with IDH inhibitors as well as potential associations between MRI metrics and progression-free survival (PFS). This evidence concerns the gene IDH1 and central nervous system cancer.